Pliant Therapeutics Inc.
11.24
-0.53 (-4.50%)
At close: Jan 14, 2025, 3:59 PM
11.24
-0.04%
After-hours Jan 14, 2025, 04:00 PM EST
undefined%
Bid 10.22
Market Cap 684.30M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -3.35
PE Ratio (ttm) -3.36
Forward PE n/a
Analyst Buy
Ask 12.9
Volume 310,170
Avg. Volume (20D) 497,418
Open 11.86
Previous Close 11.77
Day's Range 11.02 - 11.94
52-Week Range 10.22 - 18.92
Beta undefined

About PLRX

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed ...

Industry Biotechnology
Sector Healthcare
IPO Date Jun 3, 2020
Employees 166
Stock Exchange NASDAQ
Ticker Symbol PLRX

Analyst Forecast

According to 7 analyst ratings, the average rating for PLRX stock is "Buy." The 12-month stock price forecast is $41, which is an increase of 264.61% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Pliant Therapeutics Inc. is scheduled to release its earnings on Feb 26, 2025, during market hours.
Analysts project revenue of $83.33K, reflecting a n/a YoY growth and earnings per share of -0.98, making a 42.03% increase YoY.
11 months ago · Source
-9.2%
Pliant Therapeutics shares are trading lower after... Unlock content with Pro Subscription